Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Diffuse Systemic Sclerosis
NCT06546540Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of telitacicept in diffuse cutaneous systemic sclerosis (dcSSc) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: modified Rodnan Skin Score at 52 weeks and Safety and Tolerability at 52 weeks. Started Jun 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT06546540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546540.